GlycoMantra has been awarded a two-year SBIR Phase 2 grant ($3.7 M) from the NIDDK…
GlycoMantra received SBIR Phase 1 grant from the NCI (NIH)
July 18, 2018
GlycoMantra received SBIR Phase 1 grant from the NCI (NIH)
GlycoMantra was awarded SBIR Phase 1 grant to investigate drug resistance in metastatic prostate cancer.
